SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant þ
Filed by a Party other than the Registrant o

Check the appropriate box:

o   Preliminary Proxy Statement

o   Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))

þ   Definitive Proxy Statement

o   Definitive Additional Materials

o   Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12

CEPHEID

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

þ   No Fee Required.

o   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1)	Title of each class of securities to which transaction applies:
2)	Aggregate number of securities to which transaction applies:
3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
4)	Proposed maximum aggregate value of transaction:
5)	Total fee paid:

o   Fee paid previously with preliminary materials:

o   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1)	Amount Previously Paid:
2)	Form, Schedule or Registration Statement No.:
3)	Filing Party:
4)	Date Filed:

Cepheid
904 Caribbean Drive
Sunnyvale, CA 94089
(408) 541-4191

March 28, 2005

To Our Shareholders:

      I am pleased to invite you to attend the annual meeting of shareholders of Cepheid to be held at our principal executive offices, 904 Caribbean Drive, Sunnyvale, California 94089, on Thursday, April 28, 2005, at 1:00 p.m. Pacific time.

      The agenda for this year’s meeting is described in detail in the following notice of annual meeting of shareholders and proxy statement.

      The board of directors appreciates and encourages shareholder participation in Cepheid’s affairs and invites you to attend the meeting in person. It is important, however, that your shares be represented at the annual meeting in any event and for that reason we ask that whether or not you expect to attend the meeting, you take a moment to complete, date, sign and return the accompanying proxy in the enclosed postage-paid envelope. Returning the proxy does not deprive you of your right to attend the annual meeting and to vote your shares in person.

      We thank you for your support and look forward to seeing you at the meeting.

Sincerely,

/s/ John L. Bishop

John L. Bishop

Chief Executive Officer

CEPHEID

904 Caribbean Drive

Sunnyvale, California 94089

Notice of Annual Meeting of Shareholders

To Be Held on April 28, 2005

To Our Shareholders:

      Notice is hereby given that the annual meeting of the shareholders of Cepheid, a California corporation, will be held at Cepheid’s executive offices, 904 Caribbean Drive, Sunnyvale, California 94089, on Thursday, April 28, 2005, at 1:00 p.m. Pacific time for the following purposes:

1.  To elect three (3) Class III directors of Cepheid to serve on the board of directors for a three-year term. Cepheid’s board of directors intends to present the following nominees for election as Class III directors:

         Robert J. Easton

         Hollings C. Renton

         Mitchell D. Mroz

2.	To ratify the appointment of Ernst & Young LLP as independent auditors of Cepheid for the fiscal year ending December 31, 2005.
3.	To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.

      The foregoing items of business are more fully described in the proxy statement accompanying this notice. The board of directors has fixed the close of business on March 4, 2005, as the record date for the determination of shareholders entitled to notice of, and to vote at, the meeting or any adjournment.

By Order of the Board of Directors

/s/ Joseph H. Smith

Joseph H. Smith

Secretary

Sunnyvale, California

March 28, 2005

      All shareholders are cordially invited to attend the meeting in person. Whether or not you plan to attend the meeting, please complete, date, sign and return the enclosed proxy as promptly as possible in order to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) is enclosed for that purpose. Even if you have given your proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain from the record holder a proxy issued in your name. You may revoke a previously delivered proxy at any time prior to the meeting. You may do so automatically by voting in person at the meeting, or by delivering to Cepheid a written notice of revocation or a duly executed proxy bearing a date later than the date of the proxy being revoked.

TABLE OF CONTENTS

Proxy Statement for Annual Meeting of Shareholders To Be Held On April 28, 2005
Information Concerning Solicitation and Voting
	General
	Record Date
	Revocability of Proxies
	Voting and Solicitation
	Quorum, Abstentions and Broker Non-Votes
PROPOSAL NO. 1 ELECTION OF DIRECTORS
	Directors/Nominees
	Required Vote
	Board of Directors’ Meetings and Committees
	Director Compensation
	Code of Ethics
	Compensation Committee Interlocks and Insider Participation
PROPOSAL NO. 2
	Security Ownership of Certain Beneficial Owners and Management
	Executive Compensation
	Summary Compensation Table
	Stock Options Granted in the Fiscal Year Ended December 31, 2004
	Aggregated Option Exercises in Fiscal Year 2004 and Fiscal Year-End 2004 Option Values
	Related Party Transactions
	Compensation Committee Report on Executive Compensation
	Company Stock Price Performance
	Audit Committee Report
	Principal Accountant Fees and Services
	Shareholder Proposals
	Section 16(a) Beneficial Ownership Reporting Compliance
	Shareholder Communications
	Director Attendance at the Annual Meeting
	Other Business

CEPHEID

904 Caribbean Drive

Sunnyvale, CA 94089

Proxy Statement for Annual Meeting of Shareholders

To Be Held On April 28, 2005

Information Concerning Solicitation and Voting

General

      The enclosed proxy is solicited on behalf of the board of directors of Cepheid for use at the annual meeting of shareholders to be held on April 28, 2005 at 1:00 p.m. Pacific time, or at any adjournment or postponement of the meeting, for the purposes set forth in this proxy statement and in the accompanying notice of annual meeting. The annual meeting will be held at Cepheid’s executive offices, 904 Caribbean Drive, Sunnyvale, California 94089. Cepheid’s telephone number is (408) 541-4191.

      These proxy solicitation materials, together with Cepheid’s 2004 Annual Report, are being mailed on or about March 28, 2005.

Record Date

      Shareholders of record at the close of business on March 4, 2005, which we refer to as the record date, are entitled to notice of, and to vote at, the annual meeting. At the record date, approximately 42,351,265 shares of common stock were issued and outstanding.

Revocability of Proxies

      You may revoke your proxy at any time before its use by delivering to Cepheid a written notice of revocation or a duly executed proxy bearing a date later than the date of the proxy being revoked. You may also revoke your proxy by attending the annual meeting and voting in person. Attending the annual meeting will not, by itself, revoke the proxy.

Voting and Solicitation

      Shareholders are entitled to one vote for each share held as of the record date.

      Solicitation of proxies may be made by our directors, officers and other employees by personal interview, telephone, facsimile or other method. No additional compensation will be paid for these services, but we may reimburse directors, officers and employees for reasonable out-of-pocket expenses in connection with any solicitation. Costs of solicitation, including preparation, assembly, printing and mailing of this proxy statement, the proxy and any other information furnished to the shareholders, will be borne by Cepheid. We may reimburse the reasonable charges and expenses of brokerage houses, custodians, nominees, fiduciaries or others for forwarding proxy materials to, and obtaining authority to execute proxies from, beneficial owners for whose account they hold shares of common stock.

Quorum, Abstentions and Broker Non-Votes

      In the election of directors, the three candidates receiving the highest number of affirmative votes will be elected as directors. The required quorum for the transaction of business at the annual meeting is a majority of the shares of common stock issued and outstanding on the record date. Abstentions and broker non-votes will be counted for purposes of determining the presence or absence of a quorum for the transaction of business. Abstentions and broker non-votes will have no effect on the election of directors.

PROPOSAL NO. 1

ELECTION OF DIRECTORS

      Cepheid’s board of directors is divided into three classes — Class I, II and III directors. Each director is elected for a three-year term of office, with one class of directors being elected at each annual meeting of shareholders. Each director holds office until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. The size of the board is presently set at nine members.

Directors/Nominees

      The information below sets forth the current members of the board, including the nominees for Class III directors. Proxies may not be voted for more than three directors. Each person nominated for election has agreed to serve if elected and we have no reason to believe that any nominee will be unable to serve. There are no family relationships between any of the nominees, directors or any of our executive officers.

Name of Director	Age		Class		Position with Cepheid	Director Since
John L. Bishop		60		I	Chief Executive Officer and Director		2002
Robert J. Easton(2)		60		III	Director		2002
Thomas L. Gutshall		67		II	Chairman of the Board		1996
Cristina H. Kepner(1)(3)		58		II	Director		1998
Dean O. Morton(1)(2)		73		I	Director		1997
Mitchell D. Mroz(1)(3)		60		III	Director		2004
David H. Persing, M.D., Ph.D.(3)		49		II	Director		2004
Kurt Petersen, Ph.D.		57		I	Director		1996
Hollings C. Renton(2)		58		III	Director		2000

(1)	Current member of the Audit Committee.
(2)	Current member of the Compensation Committee.
(3)	Current member of the Nominating and Governance Committee.

      John L. Bishop. Mr. Bishop joined us as Chief Executive Officer and as a director in April 2002. Mr. Bishop served as President and a director of Vysis Inc, a genomic disease management company, from 1993 to 2002 and as Chief Executive Officer from 1996 to March 2002. From 1991 until November 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation and, from 1987 until 1991, of Source Scientific Systems. From 1984 to 1986, Mr. Bishop was President and Chief Operating Officer of Gen-Probe, Inc. From 1968 to 1984, Mr. Bishop held various management positions with American Hospital Supply Company and its affiliates, including a three-year assignment in Japan as an Executive Vice President and Chief Executive Officer of International Reagents Corp., a joint venture between American Hospital Supply Company and Green Cross Corporation.

      Robert J. Easton. Mr. Easton joined us as a director in January 2002. Mr. Easton is a co-founder of Easton Associates LLC, a strategic consulting firm specializing in evaluation and planning for pharmaceutical and medical device companies, and has served as their Chairman since May 2000. Prior to co-founding Easton Associates in May 2000, Mr. Easton served as Managing Director of IBM Healthcare Consulting from May 1996 to May 2000. In addition to his experience in management consulting, Mr. Easton has 12 years of managerial experience in a variety of positions in sales, marketing, planning, engineering, and operations with the industrial gas and medical products divisions of Union Carbide and Union Carbide Europe. He currently serves as a director of CollaGenex Pharmaceuticals and a private company, Afferon Corporation.

      Thomas L. Gutshall. Mr. Gutshall is a co-founder of Cepheid and has served as Chairman of the Board since August 1996. From August 1996 until April 2002, he also served as our Chief Executive Officer. From January 1995 to August 1996, he was President and Chief Operating Officer of CV Therapeutics. From 1989 to 1994, he was Executive Vice President at Syntex Corporation and a member of the Pharmaceutical Executive Committee. His responsibilities while at Syntex included managing Syva Company, Syntex

2

Agribusiness, Pharmaceutical and Chemical Operations and Services, Syntex Pharmaceutical Intl. Ltd. and Environmental Health and Safety. Mr. Gutshall currently serves as a director of CV Therapeutics, Metrika, Inc. and Satoris Corporation.

      Cristina H. Kepner. Ms. Kepner joined us as a director in May 1998. She is currently an advisor to Invemed Associates, LLC, an investment banking firm. She has been with Invemed since 1978, where she has served in a variety of capacities. Prior to becoming advisor to the President at Invemed, Ms. Kepner served as Executive Vice President and Corporate Finance Director until December 31, 2000. Ms. Kepner also served as a director of Invemed until December 2000. Ms. Kepner currently serves as a director of ViroLogic, Inc. and is the Chairman of the Board of Quipp, Inc.

      Dean O. Morton. Mr. Morton joined us as a director in July 1997. Mr. Morton has been retired for the past six years. He was Executive Vice President, Chief Operating Officer and a director of Hewlett-Packard Company from 1960 to 1992. Mr. Morton currently serves as a director of BEA Systems, Inc. and Pharsight Corporation, and a private company, KT Venture Group. He is a trustee of the State Street Research group of mutual funds and a director of the Met Life Series Funds Group. He serves on the Board of Monterey Bay Aquarium Research Institute and Center for Excellence in Non Profits.

      Mitchell D. Mroz. Mr. Mroz joined us as a director in May 2004. Mr. Mroz is currently Chairman of the Board of Northrop Grumman’s Federal Credit Union and is retired from Northrop Grumman Corporation. Since joining Northrup Grumman in 1978, he served in various capacities, including the positions of Vice President and Chief Financial Officer for Grumman Corporation and Vice President and General Manager of the Automation and Information Systems Division of Northrop Grumman, Corporate Vice President Internal Audit and Audit Manager. Before joining Northrop Grumman, he was an Auditor for the U.S. Air Force Audit Agency and the U.S. General Accounting Office.

      David H. Persing, M.D., Ph.D. Dr. Persing joined us as a director in May 2004. Dr. Persing is currently Vice President of Discovery Research at Corixa Corporation, a company that develops immunotherapeutic products. He has been with Corixa since 1999. He is also Medical Director of the Infectious Disease Research Institute. In 1992, Dr. Persing established and directed the Molecular Microbiology Laboratory at Mayo Clinic Rochester. Prior to that, he was a member of the Mayo Clinic Staff where he developed research programs on hepatitis viruses and on the immunological interactions of tick-borne infections.

      Kurt Petersen, Ph.D. Dr. Peterson has been a director since August 1996. Dr. Peterson is currently the Chief Executive Officer and a director of SiTime, Inc. Dr. Petersen co-founded Cepheid and served as our President from August 1996 to August 2004, our Chief Operating Officer from August 1996 to April 2003 and our Chief Technical Officer from April 2003 to August 2004. From January 1996 through July 1996, Dr. Petersen worked as a private consultant. From 1985 to 1995, he served as Vice President, Technology for NovaSensor. He holds over 20 patents and has authored over 80 technical papers and presentations. Dr. Petersen is a Fellow of the Institute of Electrical and Electronics Engineers (IEEE) and a member of the National Academy of Engineering. In 2001, he was awarded the Simon Ramo medal by the IEEE.

      Hollings C. Renton. Mr. Renton joined us as a director in March 2000. Since 1993, he has served as President and Chief Executive Officer and a director of Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company. From 1991 to 1993, he served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. Prior to the acquisition, he served as President of Cetus Corporation from 1990 to 1991 and as Chief Operating Officer from 1987 to 1990. Mr. Renton currently serves as a director of Rigel Pharmaceuticals.

Required Vote

      The three nominees receiving the highest number of affirmative votes of the shares present or represented and entitled to vote will be elected as directors. If signed and returned, shares represented by the accompanying proxy will be voted for the election of the nominees recommended by the board unless the proxy is marked in such a manner as to withhold authority so to vote. If any nominee for any reason is unable

3

to serve or for good cause will not serve, the proxies may be voted for a substitute nominee determined by the proxy holder.

      The board recommends a vote for the election of the nominated directors.

Board of Directors’ Meetings and Committees

      The board currently consists of nine members. The board of directors has affirmatively determined that all directors, other than John L. Bishop, Thomas L. Gutshall and Kurt Petersen, are independent under NASDAQ listing standards and applicable Securities and Exchange Commission rules. The board met six times, including three telephone conference meetings, during 2004. No director attended fewer than 75% of the aggregate of: (i) the total number of meetings of the board held during the period for which he or she was a director and, (ii) the total number of meetings held by all committees of the board on which he or she served during the period that he or she served. Standing committees of the board include an audit committee, a compensation committee and a nominating and governance committee. Each of these committees has a written charter approved by the board of directors.

      Audit Committee. Cristina H. Kepner, Dean O. Morton and Mitchell D. Mroz are the current members of Cepheid’s audit committee. All members of the audit committee meet the independence and financial experience requirements under both Securities and Exchange Commission rules and NASDAQ listing standards. The board has determined that Cristina H. Kepner, Dean O. Morton and Mitchell D. Mroz are “audit committee financial experts” as such term is defined in applicable rules of the Securities and Exchange Commission. The Audit Committee met seven times, including four telephone conference meetings, in 2004. The audit committee hires the independent auditors, reviews the scope of audit and pre-approves permissible non-audit services by our independent auditors, reviews the accounting principles and auditing practices and procedures to be used for our financial statements, reviews the results of those audits, annually reviews the audit committee charter, and reviews related party transactions. The audit committee charter was filed as Appendix A to our proxy statement dated April 29, 2003 and is available under the “Investor Relations” section of our website at www.cepheid.com.

      Compensation Committee. Dean O. Morton, Hollings C. Renton and Robert J. Easton are the current members of Cepheid’s compensation committee. All members of the compensation committee meet the independence requirements under the NASDAQ listing standards. The compensation committee met six times, including three telephone conference meetings, in 2004. The compensation committee is responsible for reviewing the compensation and benefits for Cepheid’s executive officers and administering the company’s compensation plans, as well as supervising and making recommendations to the board on compensation matters generally. The compensation committee charter is available under the “Investor Relations” section of our website at www.cepheid.com.

      Nominating and Governance Committee. Cristina H. Kepner, David H. Persing and Mitchell D. Mroz are the current members of Cepheid’s nominating and governance committee. All members of the nominating and governance committee meet the independence requirements under the NASDAQ listing standards. The nominating and governance committee held one meeting in 2004. The nominating and governance committee considers and recommends to the board candidates to serve as members of the board, develops and maintains a set of corporate governance guidelines and establishes procedures for director nomination. In making recommendations to the board regarding candidates to serve as members of the board, the nominating and governance committee considers the recommendations of board members, members of management and shareholders (if made in accordance with Cepheid’s charter documents and applicable law). The nominating and governance committee may retain recruiting professionals to identify and evaluate candidates for director nominees. The nominating and governance committee charter is available under the “Investor Relations” section of our website at www.cepheid.com.

      In selecting nominees for the board of directors, the committee will assess a number of factors, including the independence, experience and judgment of candidates and endeavors to collectively support a number of areas of core competency on the board, including business judgment, management experience, accounting and

4

financial acumen, industry and technology knowledge, leadership, strategic vision and willingness to devote sufficient time to attend meetings and participate effectively on the board of directors.

      Potential candidates are screened and interviewed by the nominating and governance committee. All members of the board may interview the final candidates. The same identifying and evaluating procedures will apply to all candidates for director nomination, including candidates submitted by shareholders.

      Shareholders can recommend qualified candidates for the board by submitting, in accordance with our bylaws, the candidate’s name and qualifications to: Joseph H. Smith, Secretary, Cepheid, 904 Caribbean Drive, Sunnyvale, California 94089. The committee requests that submissions be made as early as possible to ensure meaningful consideration by the committee.

Director Compensation

      We pay our non-employee directors an annual retainer of $15,000. Our non-employee Chairman of the Board receives an additional $15,000 per year. The non-employee Chairs of our Audit Committee, Compensation Committee and Nominating and Governance Committee receive an additional $5,000, $4,000 and $2,500 in annual compensation, respectively. Our non-employee directors each receive $1,500 per board meeting attended in person, and $1,000 per committee meeting attended in person, and $500 per board or committee meeting attended by telephone or other remote means of communication. We also reimburse our non-employee directors for expenses incurred in connection with attending board and committee meetings.

      New non-employee directors receive non-discretionary, automatic grants of options pursuant to our 1997 Stock Option Plan to purchase 15,000 shares of our common stock upon joining the board, and our continuing non-employee directors receive non-discretionary, automatic grants of options pursuant to our 1997 Stock Option Plan to purchase 7,500 shares of our common stock after each annual meeting of shareholders. Options granted to new non-employee directors upon joining our board will become vested and exercisable with respect to 5,000 shares on each one-year anniversary of the grant date, so long as the person remains a director of Cepheid. Options granted to our continuing non-employee directors after each annual meeting of shareholders will become fully vested and exercisable on the one-year anniversary of the grant date, so long as the person remains a director of Cepheid. All option grants to non-employee directors under the 1997 Stock Option Plan will become fully vested and exercisable immediately prior to Cepheid’s dissolution, liquidation, merger with or into another corporation, or sale of all or substantially all of our assets, and will expire three months after the event that caused the vesting acceleration to the extent they have not been previously exercised. All options granted to non-employee directors under the 1997 Stock Option Plan will have an exercise price equal to the current fair market value of our common stock on the date of the grant, and will be nonqualified stock options.

Code of Ethics

      We have adopted a code of ethics that applies to our Chief Executive Officer and senior financial officers, including our chief financial officer and controller. This code of ethics is available under the “Investor Relations” section of our website at www.cepheid.com.

Compensation Committee Interlocks and Insider Participation

      No member of our compensation committee was at any time during 2004, or at any other time, an officer or employee of Cepheid. No executive officer of Cepheid serves as a member of the board of directors or compensation committee of any entity that has one or more of our executive officers serving as a member of our board or compensation committee.

5

PROPOSAL NO. 2

RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS

      The board has selected Ernst & Young LLP, independent auditors, to audit our financial statements for the fiscal year ending December 31, 2005. Ernst & Young LLP has audited our financial statements since our inception. Representatives of Ernst & Young LLP are expected to be present at the annual meeting and will have the opportunity to make a statement if they desire to do so, and are expected to be available to respond to appropriate questions.

      The board recommends a vote for the ratification of the appointment of

Ernst & Young LLP as our independent auditors.

Security Ownership of Certain Beneficial Owners and Management

      The following table sets forth the beneficial ownership of our common stock as of March 4, 2005 by each of the named executive officers set forth in the compensation table and each director and all executive officers and directors as a group.

      Percentage of ownership is based on 42,351,265 shares of common stock outstanding as of March 4, 2005. Beneficial ownership is calculated based on Securities and Exchange Commission requirements. All shares of common stock subject to stock options currently exercisable or exercisable within 60 days after March 4, 2005 are deemed to be outstanding for the purpose of computing the percentage of ownership of the person holding the stock options, but are not deemed to be outstanding for computing the percentage of ownership of any other person. Unless otherwise indicated below, each shareholder named in the table has sole or shared voting and investment power with respect to all shares beneficially owned, subject to applicable community property laws. Unless otherwise indicated in the table, the address of each individual listed in the table is Cepheid, 904 Caribbean Drive, Sunnyvale, California 94089.

	Number of		Percentage
	Shares		of Shares
	Beneficially		Beneficially
Beneficial Owner	Owned		Owned
Directors and Named Executive Officers
John L. Bishop(1)		800,000		1.9	%
Robert J. Easton(2)		92,410		*
Russel K. Enns(3)		76,875		*
Thomas L. Gutshall(4)		1,262,241		3.0
Cristina H. Kepner(5)		138,232		*
Ira Marks(6)		67,333		*
Dean O. Morton(7)		173,000		*
Mitchell D. Mroz(8)		7,000		*
David H. Persing, M.D., Ph.D.(9)		5,000		*
Kurt Petersen, Ph.D.(10)		823,257		1.9
Hollings C. Renton(11)		73,000		*
John R. Sluis(12)		277,500		*
Joseph H. Smith(13)		123,541		*
All executive officers and directors as a group of 15 persons(14)		3,919,389		8.8
Five Percent Shareholders
Alliance Capital Management(15)		5,940,325		14.0	%
Kopp Investment Advisors(16)		3,857,980		9.1

6

* Less than one percent.

(1)	Consists of options to purchase 800,000 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 268,750 of the shares issuable upon exercise of these options are unvested.
(2)	Consists of options to purchase 30,000 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 7,500 of the shares issuable upon exercise of these options are unvested.
(3)	Consists of options to purchase 76,875 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 11,250 shares issuable upon exercise of these options are unvested.
(4)	Consists of options to purchase 250,000 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 28,126 of the shares issuable upon exercise of these options are unvested.
(5)	Consists of options to purchase 73,000 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 7,500 of the shares issuable upon exercise of these options are unvested.
(6)	Consists of options to purchase 65,833 shares exercisable within 60 days of March 4, 2005.
(7)	Includes 77,500 shares held of record by MDLC Partners, a California Limited partnership, of which Mr. Morton is the general partner. Mr. Morton also has options to purchase 25,000 shares. As of March 4, 2005, 7,500 of the shares issuable upon exercise of these options are unvested.
(8)	Consists of options to purchase 5,000 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 5,000 of the shares issuable upon exercise of these options are unvested.
(9)	Consists of options to purchase 5,000 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 5,000 of the shares issuable upon exercise of these options are unvested.

(10)	Consists of options to purchase 215,000 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 43,126 of the shares issuable upon exercise of these options are unvested.
(11)	Consists of options to purchase 73,000 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 7,500 of the shares issuable upon exercise of these options are unvested.
(12)	Consists of options to purchase 277,500 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 108,568 of the shares issuable upon exercise of these options are unvested.
(13)	Consists of options to purchase 123,541 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 14,166 of the shares issuable upon the exercise of these options are unvested.
(14)	Includes options to purchase 2,019,749 shares exercisable within 60 days of March 4, 2005. As of March 4, 2005, 513,986 of the shares issuable upon the exercise of these options are unvested.
(15)	Based on a Schedule 13G/ A filed February 14, 2005. According to the schedule of these shares, 5,637,845 are held by Alliance Capital Management, L.P. on behalf of client discretionary accounts, and 302,480 are held by AXA Equitable Life Insurance Company. Both of these entities are direct or indirect subsidiaries of AXA Financial, Inc., AXA and the Mutuelles AXA. Alliance Capital Management’s address is 26, rue Drouot, 75009 Paris, France.
(16)	Based on a Schedule 13G/ A filed January 21, 2005. According to the schedule of these shares, 3,557,980 are held by Kopp Investment Advisors and 320,000 are held by LeRoy C. Kopp, who controls Kopp Investment Advisors through two holding companies. According to this Schedule, 3,667,980 shares are held in fiduciary or representative capacity, with no person individually having an interest that relates to more than 5% of the common stock. Kopp Investment Advisors’ address is 7701 France Avenue South, Suite 500, Edina, Minnesota 55435.

7

Executive Compensation

      The following table sets forth the compensation paid by Cepheid during 2004, 2003 and 2002 to the Chief Executive Officer and to Cepheid’s four other most highly compensated executive officers. We refer to these individuals as the named executive officers.

Summary Compensation Table

										Long Term
										Compensation
										Awards
						Annual Compensation
										Number of
								Other Annual		Securities		All Other
Name and Position		Year		Salary		Bonus		Compensation(1)		Underlying Options		Compensation(2)
John L. Bishop(3)			2004	$	330,270	$	116,000	$	42,383		200,000	$	1,980
	Chief Executive Officer		2003		310,000		58,125		63,105		—		1,340
			2002		215,808		77,500		34,370		750,000		932
Russel K. Enns(4)			2004		207,846		—		—		20,000		815
	Sr. Vice President, Regulatory		2003		110,769		—		95,767		150,000		446
	and Clinical Affairs		2002		—		—		—		—		—
Ira Marks(5)			2004		227,274		28,500		—		—		913
	Vice President, Worldwide		2003		64,903		17,631		104,602		200,000		149
	Sales and Marketing		2002		—		—		—		—		—
John R. Sluis(6)			2004		241,346		—		46,019		50,000		987
	Sr. Vice President, Finance		2003		225,000		—		68,837		—		903
	and Chief Financial Officer		2002		100,385		—		19,414		265,000		1,361
Joseph H. Smith(7)			2004		263,077		—		—		15,000		1,688
	Sr. Vice President, Legal/		2003		138,942		—		—		250,000		546
	Business Development and		2002		—		—		—		—		—
	General Counsel

(1)	Consists of reimbursement of relocation and commuting expenses.
(2)	Consists of value of employee life insurance and health insurance.
(3)	Mr. Bishop joined us in April 2002.
(4)	Mr. Enns joined us in June 2003.
(5)	Mr. Marks joined us in September 2003 and resigned in February 2005.
(6)	Mr. Sluis joined us in July 2002.
(7)	Mr. Smith joined us in June 2003.

8

Stock Options Granted in the Fiscal Year Ended December 31, 2004

      The following table sets forth information with respect to stock options granted during the fiscal year ended December 31, 2004 to each of our named executive officers. All options were granted under Cepheid’s 1997 Stock Option Plan.

      The percentage of options granted is based on an aggregate of 1,585,450 options granted by Cepheid during the fiscal year ended December 31, 2004 to Cepheid’s employees, including the named executive officers. The potential realizable value amounts in the last two columns of the following chart represent hypothetical gains that could be achieved for the respective options if exercised at the end of the option term. The assumed 5% and 10% annual rates of stock price appreciation from the date of grant to the end of the option term are provided in accordance with rules of the Securities and Exchange Commission and do not represent Cepheid’s estimate or projection of the future common stock price. Actual gains, if any, on stock option exercises are dependent on the future performance of the common stock, overall market conditions and the option holder’s continued employment through the vesting period.

	Individual Grants
			% of Total							Potential Realizable Value
	Number of		Options							at Assumed Annual Rates
	Securities		Granted to			Exercise				of Stock Price Appreciation
	Underlying		Employees			Price				for Option Terms
	Options		in Fiscal			Per		Expiration
Name	Granted		Year			Share		Date		5%		10%
John L. Bishop(1)		200,000		12.61	%	$	7.35		4/29/2014	$	924,475	$	2,342,801
Russel K. Enns(2)		20,000		1.26			7.35		4/29/2014		92,448		234,280
Ira Marks		—		—			—		—		—		—
John R. Sluis(3)		50,000		3.15			7.35		4/29/2014		231,119		585,700
Joseph H. Smith(4)		15,000		0.95			7.35		4/29/2014		69,335		175,710

(1)	As of March 4, 2005, all of the shares issuable upon exercise of Mr. Bishop’s option are unvested.
(2)	As of March 4, 2005, all of the shares issuable upon exercise of Mr. Enns’s option are unvested.
(3)	As of March 4, 2005, all of the shares issuable upon exercise of Mr. Sluis’s option are unvested.
(4)	As of March 4, 2005, all of the shares issuable upon exercise of Mr. Smith’s option are unvested.

Aggregated Option Exercises in Fiscal Year 2004 and Fiscal Year-End 2004 Option Values

      The following table sets forth certain information regarding unexercised options held as of December 31, 2004 by each of the named executive officers. No options were exercised by any of the named executive officers in 2004. All options listed in the table below were granted under the 1997 Stock Option Plan.

					Number of Securities				Value of Unexercised In-the
					Underlying Unexercised				Money Options at
	Shares				Options at Fiscal Year-End				Fiscal Year-End(1)
	Acquired on		Value
Name	Exercise		Realized		Exercisable		Unexercisable		Exercisable		Unexercisable
John L. Bishop(2)		—	$	—		750,000		200,000	$	4,747,500	$	518,000
Russel K. Enns(3)		—		—		56,250		113,750		316,688		579,613
Ira Marks(4)		—		—		62,500		137,500		286,875		631,125
John R. Sluis(5)		—		—		265,000		50,000		1,497,250		129,500
Joseph H. Smith(6)		—		—		93,750		171,250		528,750		920,100

(1)	These values have been calculated on the basis of the fair market value of our common stock on December 31, 2004, $9.94, less the applicable exercise price per share, multiplied by the number of shares underlying the options.
(2)	As of March 4, 2005, 418,750 of the shares issuable upon exercise of Mr. Bishop’s option are unvested.
(3)	As of March 4, 2005, 104,375 of the shares issuable upon exercise of Mr. Enns’ options are unvested.

9

(4)	As of March 4, 2005, 129,167 of the shares issuable upon exercise of Mr. Marks’ options are unvested, these shares were subsequently cancelled following the resignation of Mr. Marks.
(5)	As of March 4, 2005, 146,068 of the shares issuable upon exercise of Mr. Sluis’ option are unvested.
(6)	As of March 4, 2005, 155,625 of the shares issuable upon exercise of Mr. Smith’s option are unvested.

Securities Authorized For Issuance Under Equity Compensation Plans

      The following table sets forth certain information, as of December 31, 2004, concerning securities authorized for issuance under all equity compensation plans of Cepheid:

						Number of Securities
		Number of Securities				Remaining Available for
		to Be Issued upon		Weighted-Average		Future Issuance under
		Exercise of		Price of		Equity Compensation Plans
		Outstanding Options,		Outstanding Options,		(Excluding Securities
Plan Category		Warrants and Rights		Warrants and Rights		Reflected in Column (a))
		(a)		(b)		(c)
Equity Compensation plans approved by the shareholders(1)			5,597,564	$	5.54		768,955
Equity compensation plans not approved by the shareholders			—		N/A		—
	Total		5,597,564				768,955

(1)  Includes our 1997 Stock Option Plan, our 2000 Employee Stock Purchase Plan and our 2000 Non-Employee Directors’ Stock Option Plan.

Related Party Transactions

      John L. Bishop Employment Agreement. We entered into an employment agreement with John L. Bishop in March 2002. The employment agreement specified that Mr. Bishop’s annual base salary will be $310,000, to be reviewed annually and an initial guaranteed bonus of $77,500. In future years, the employment agreement provides that Mr. Bishop will be eligible to receive an annual bonus equal to up to 25% of his base annual salary, with the percentage being determined by the degree of achievement of certain performance goals and objectives to be determined by Mr. Bishop and the compensation committee. During fiscal 2004, the compensation committee reviewed Mr. Bishop’s compensation package and third-party market data for chief executive officers at comparable companies and determined that Mr. Bishop’s annual base salary would be increased to $341,000 and that he would be eligible to receive an annual bonus in future years in an amount equal to up to 40% of his annual base salary. Under his employment agreement, Mr. Bishop also received an immediately exercisable option to purchase 750,000 shares of our common stock at an exercise price of $3.61 per share, which was equal to the fair market value on the date of grant. Twenty-five percent of the shares of common stock issuable upon exercise of this option vested on April 12, 2003, and the remainder vest in equal monthly installments over three years, so long as Mr. Bishop continues to be employed by Cepheid. Mr. Bishop received an additional option to purchase 200,000 shares of our common stock during fiscal 2004.

      Upon termination other than for cause, or upon a constructive termination, Mr. Bishop will receive a lump sum payment equal to 12 months of his then current base salary, a prorated target cash bonus based on the degree of achievement of certain performance goals and objectives by Mr. Bishop prior to his termination, and 50% of all unvested shares will become vested shares. If Mr. Bishop is terminated without cause or he is constructively terminated within one year of a change of control event, Mr. Bishop will receive a lump sum payment equal to 18 months base salary and prorated target cash bonus, and all unvested shares will become vested shares.

      Cause is defined in Mr. Bishop’s employment agreement to mean:

•  a failure to perform his duties after notice and an opportunity to cure;

•  misconduct injurious to us;

10

•  a conviction of, or a guilty or no contest plea to, a felony charge;

•  acts of fraud against us, misappropriation of our property or dishonesty affecting our business or affairs; or

•  a breach of any agreement with us, including those regarding confidentiality and proprietary information: or

•  a failure or refusal to carry out the reasonable directives of Cepheid, following notice and an opportunity to cure.

      Constructive termination, as defined in Mr. Bishop’s employment agreement, means Mr. Bishop’s voluntary termination of his employment with us due to:

•  a specified reduction in his responsibilities, salary or target bonus;

•  our material breach of his employment agreement;

•  a forced relocation of his primary workplace; or

•  the failure of any successor of Cepheid to assume his employment agreement.

      John R. Sluis Employment Agreement. We entered into an employment agreement with John R. Sluis in March 2002. The employment agreement specified that Mr. Sluis’ annual base salary will be $225,000, to be reviewed annually. During fiscal 2004, the compensation committee reviewed Mr. Sluis’ compensation package and third-party market data for chief financial officers at comparable companies and determined that Mr. Sluis’ annual base salary would be increased to $250,000. Under his employment agreement, Mr. Sluis also received an immediately exercisable option to purchase 265,000 shares of our common stock at an exercise price of $4.29 per share, which was equal to the fair market value on the date of grant. Twenty-five percent of the shares issuable upon exercise of this option vested on July 12, 2003 and the remainder vests in equal monthly installments over three years so long as Mr. Sluis continues to be employed by Cepheid. Mr. Sluis received an additional option to purchase 50,000 shares of our common stock during fiscal 2004.

      If Mr. Sluis is terminated without cause or he is constructively terminated within one year of a change of control event, Mr. Sluis will receive a lump sum payment equal to 15 months base salary, and all unvested shares will become vested shares. The definitions of cause and constructive termination in Mr. Sluis’ employment agreement are to the same as those in Mr. Bishop’s employment agreement, except that portion of the constructive termination definition relating to a specified reduction in target bonus is not applicable to Mr. Sluis.

      Humberto Reyes Employment Offer Letter. We entered into an employment offer letter with Humberto Reyes, our Senior Vice President, Operations, in November 2004. Under the offer letter, Mr. Reyes will receive an annual salary of $250,000, and was granted an option to purchase 135,000 shares of our common stock at an exercise price equal to the fair market value of our common stock on the date of grant. We also entered into a change of control and severance agreement with Mr. Reyes that is described below.

      Robert Koska Employment Offer Letter. We entered into an employment offer letter with Robert Koska, our Senior Vice President of Sales & Marketing, in February 2005. Under the offer letter, Mr. Koska will receive an annual salary of $225,000, and was granted an option to purchase 200,000 shares of our common stock at an exercise price equal to the fair market value of our common stock on the date of grant. Mr. Koska will also be entitled to receive an annual bonus of up to 25% of his base salary. We also entered into a change of control and severance agreement with Mr. Koska that is described below.

      Change of Control Retention and Severance Agreements for Russel K. Enns, Joseph H. Smith, Humberto Reyes and Robert Koska. We amended the change of control retention and severance agreements with Russel K. Enns and Joseph H. Smith in May 2004. We also entered into a change of control retention and severance agreement with Mr. Reyes in November 2004 and Mr. Koska in February 2005. Under these agreements, if a termination of employment by Cepheid other than for cause, or a termination by the executive following a diminution of responsibilities, occurs within one year of a change of control event, the

11

employee will receive a lump sum payment equal to 15 months base salary, and all outstanding shares and stock options held by such person prior to the change of control event will become fully vested and exercisable.

      Cause is defined in the change of control retention and severance agreement to mean:

•  failure to perform any reasonable and lawful duty of his position or failure to follow the lawful written directions of the Chief Executive Officer;

•  commission of an act that constitutes misconduct and is injurious to the company or any subsidiary;

•  conviction of, or pleading “guilty” or “no contest” to, a felony under the laws of the United States or any state thereof;

•  committing an act of fraud against, or the misappropriation of property belonging to, the company or any subsidiary;

•  commission of an act of dishonesty in connection with his responsibilities as an employee and affecting the business or affairs of the company;

•  breach of any confidentiality, proprietary information or other agreement with the company or any subsidiary; or

•  failure or refusal to carry out the reasonable directives of the company.

      Ira Marks Separation Agreement. Effective March 2, 2005, the Company entered into a Separation Agreement with Ira Marks, its former Vice President, Worldwide Sales & Marketing. Under this agreement, Mr. Marks will receive a severance payment in the amount of $114,100, which constitutes six months of his former annual base salary, and the use of an executive outplacement service for six months. As part of this agreement, Mr. Marks also released the Company from any claims he may have against it.

Compensation Committee Report on Executive Compensation

      This report of the compensation committee is required by the Securities and Exchange Commission and is not “soliciting material,” is not to be deemed “filed” with the Securities and Exchange Commission and is not to be incorporated by reference in any filing of Cepheid under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filing.

Introduction

      The compensation committee of the board of directors is responsible for reviewing the compensation and benefits for Cepheid’s executive officers, as well as supervising and making recommendations to the board of directors on compensation matters generally. The compensation committee also administers Cepheid’s equity incentive plans and makes grants to executive officers under the 1997 Stock Option Plan. The current members of the compensation committee are Robert J. Easton, Dean O. Morton and Hollings C. Renton, each of whom meets the independence requirements of the NASDAQ listing standards, is a “non-employee director” within the meaning of Section 16 of the Exchange Act, and an “outside director” within the meaning of Section 162(m) of the Internal Revenue Code.

      The compensation committee meets at scheduled times during the year and holds additional meetings from time to time to review and discuss executive compensation issues. The compensation committee also considers and takes action by written consent. The compensation committee has the authority to engage the services of outside advisers, experts and others to assist the committee and determine the compensation of such persons.

      The compensation committee’s charter adopted by the board of directors in July 2004 reflects these various responsibilities. The compensation committee charter is posted under the “Investor Relations” section of our website at www.cepheid.com.

12

General Compensation Policy

      The compensation committee acts on behalf of the board of directors to establish the general compensation policy of Cepheid. The compensation committee’s philosophy in compensating executive officers, including the Chief Executive Officer, is to relate compensation to corporate performance. Consistent with this philosophy, the incentive component of our executive officers’ compensation is based on our corporate results and sales performance. Long-term equity compensation for executive officers is made through stock option grants. Stock options provide value only if our stock price increases (which benefits all shareholders) above the price at which the option was granted, and then only if the optionee continues to provide services to us during the option’s vesting schedule.

      The compensation committee typically reviews annual base salary levels and target bonuses for our Chief Executive Officer and our other executive officers and employees at or about the beginning of each calendar year.

      The base salaries, incentive compensation and stock option grants of the executive officers are determined in part by the compensation committee reviewing data on prevailing compensation practices in companies with whom we compete for executive talent and by their evaluating this information in connection with our corporate goals. Subject to the limitations regarding available data, the compensation committee compared the compensation of our executive officers with the compensation practices of comparable companies to determine annual base salary, target annual cash bonuses and target total cash compensation (base salary and cash bonuses). Our executive officers, including the Chief Executive Officer, are eligible to participate in our 1997 Stock Option Plan and our 2000 Employee Stock Purchase Plan.

Fiscal 2004 Executive Compensation

      Base Compensation. The compensation committee reviewed the recommendations and performance and market data outlined above and established a base salary level for each executive officer.

      Stock Options. In fiscal 2004, we granted options to purchase shares of our common stock to some of our executive officers to aid in their retention and to align their interests with those of the shareholders by providing them with an equity stake in us. Stock options typically are granted to executive officers when the executive first joins us, in connection with a significant change in responsibilities and, occasionally, to achieve equity within a peer group. The compensation committee may, however, grant additional stock options to executives for other reasons. The number of shares subject to each option granted is within the discretion of the compensation committee and is based on the optionee’s anticipated future contribution to us and his or her ability to influence corporate results, past performance and consistency within his or her peer group. In fiscal 2004, the compensation committee considered the factors described above, as well as the number of unvested stock options held by the executive officers as of the date of grant. Stock options are granted at a price per share that is equal to 100% of the fair market value of our common stock on the date of grant. The vesting for stock options granted to our executive officers in fiscal 2004 was designed to further ensure the retention of the executive officers.

Chief Executive Officer Compensation

      John L. Bishop has served as our Chief Executive Officer since April 2002. Mr. Bishop’s base salary for fiscal 2004 was $341,000, which represents a 10% increase from 2003. Mr. Bishop was awarded a bonus of $116,000 for 2004. He will be eligible to receive an annual bonus in future years in an amount equal to up to 40% of his annual base salary. Mr. Bishop also received an option to purchase 200,000 shares of our common stock during 2004. This option was granted at 100% of fair market value on the date of grant and is subject to monthly vesting over a four-year period beginning on the date of grant. In 2003, Mr. Bishop did not receive an option to purchase shares of our common stock.

      The compensation committee considered many factors in determining whether to increase Mr. Bishop’s annual base salary for fiscal 2004, the amount of his annual bonus based on his performance in fiscal 2004 and the number of stock options to grant him. In conducting this assessment, the compensation committee

13

considered Cepheid’s accomplishments under Mr. Bishop’s leadership during fiscal 2004, including Mr. Bishop’s performance against the strategic and operational goals and financial milestones that the committee had established at the beginning of fiscal 2004 regarding Mr. Bishop.

Non-Executive Compensation

      In fiscal 2003 and 2004, the compensation committee engaged an outside compensation consulting firm to provide market data on the compensation practices of similarly situated high-technology companies. Over several months, the compensation committee met on numerous occasions to review, discuss and analyze the data compiled by and presented to it by its compensation consultant in light of Cepheid’s overall compensation structure. Following its review and based upon recommendations from Cepheid’s management, the compensation committee adopted a graded salary structure that provides management the ability to hire and make compensation decisions for employees who are not directors or executive officers of Cepheid and that are within established guidelines for salaries and equity awards.

      The compensation committee has delegated to two members of our board of directors, Mr. Bishop and Dr. Kurt Petersen, the authority acting together to grant stock options under our 1997 Stock Option Plan to our employees and other service-providers who are not directors or executive officers of Cepheid subject to established guidelines that are based upon the salary grade of new hires and existing employees.

Compliance with Internal Revenue Code Section 162(m)

      Section 162(m) of the Internal Revenue Code of 1986, as amended, limits the tax deduction to $1 million for compensation paid to certain executives of public companies. However, performance-based compensation that has been approved by shareholders is excluded from the $1 million limit if, among other requirements, the compensation is payable only upon attainment of pre-established, objective performance goals and the board committee that establishes the goals consists only of “outside directors.” Additionally, stock options will qualify for the performance-based exception where, among other requirements, the exercise price of the stock option is not less than the fair market value of the stock on the date of grant, and the plan includes a per-executive limitation on the number of shares for which stock options may be granted during a specified period. All members of the compensation committee qualify as outside directors within the meaning and as defined by Section 162(m) of the Internal Revenue Code of 1986, as amended, and the regulations thereunder. Historically, the combined salary and bonus of each executive officer has been below this $1 million limit. The compensation committee’s present intention is to grant future compensation that does not exceed the limitations of Section 162(m).

Conclusion

      Through the plans and policies described above, a significant portion of Cepheid’s executive compensation is based on corporate and individual performance, as well as competitive pay practices. The compensation committee believes equity compensation is vital to the long-term success of Cepheid. The compensation committee remains committed to this policy, recognizing the competitive market for talented executives. Going forward the compensation committee intends to continue to evaluate Cepheid’s executive compensation plans, policies and programs, and will consider, among other things, the accounting treatment of stock options, dilution, the incentive value of various equity vehicles, the role of cash and equity and the need to retain key talent. The compensation committee believes that long-term stockholder value was enhanced by the corporate and individual performance achievements of Cepheid’s executives in 2004.

COMPENSATION COMMITTEE

Robert J. Easton

Dean O. Morton

Hollings C. Renton

14

Company Stock Price Performance

      The following graph shows the total shareholder return of an investment of $100 in cash on June 21, 2000, the date Cepheid’s common stock began to trade on the NASDAQ National Market, through December 31, 2004, the last date of trading of fiscal 2004 for (1) Cepheid’s common stock, (2) the NASDAQ Biotechnology Index and the NASDAQ Composite Index. All values assume reinvestment of the full amount of all dividends. No cash dividends have been declared on shares of Cepheid’s common stock. Shareholder returns over the indicated period are based on historical data and are not necessarily indicative of future shareholder returns.

TOTAL RETURN TO STOCKHOLDERS

(Assumes $100 investment on 06/21/00)

Total Return Analysis	6/21/2000		12/29/2000		12/31/2001		12/31/2002		12/31/2003		12/31/2004
Cepheid	$	100.00	$	91.22	$	46.16	$	56.54	$	108.43	$	107.46
NASDAQ Biotechnology	$	100.00	$	92.51	$	75.45	$	43.20	$	62.38	$	65.55
NASDAQ Composite	$	100.00	$	64.25	$	53.56	$	36.07	$	52.18	$	56.57

      This section is not “soliciting material,” is not to be deemed “filed” with the Securities and Exchange Commission and is not to be incorporated by reference in any filing of Cepheid under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filing.

Audit Committee Report

      This report of the audit committee is required by the Securities and Exchange Commission, and is not “soliciting material,” is not to be deemed “filed” with the Securities and Exchange Commission and is not to be incorporated by reference in any filing of Cepheid under the Securities Act of 1933, or the Securities Exchange Act of 1934, whether made before or after the date hereof and irrespective of any general incorporation language in any filing.

      Under the guidance of the amended charter adopted by the board of directors in September 2002, the purpose of the audit committee is to:

•  monitor the integrity of Cepheid’s financial statements;

15

•  monitor the periodic reviews of Cepheid’s accounting and financial reporting process and systems of internal control that are conducted by Cepheid’s independent auditors and Cepheid’s financial and senior management;

•  review and evaluate the independence and performance of Cepheid’s independent auditors, approve all audit and non-audit services to be performed by the auditors and appoint, oversee and compensate Cepheid’s independent auditors; and

•  hire the independent auditors, evaluate the independent auditors and, where appropriate, replace the independent auditors.

      Each of the members of the audit committee meets the independence and financial experience requirements of the Securities and Exchange Commission and the NASDAQ listing standards. Cristina H. Kepner, Dean O. Morton and Mitchell D. Mroz are “audit committee financial experts” as such term is defined in applicable rules of the Securities and Exchange Commission. The audit committee charter is posted under the “Investor Relations” section of our website at www.cepheid.com.

      Management has the primary responsibility for the system of internal controls and the financial reporting process, and for the preparation of financial statements in accordance with generally accepted accounting principles. The independent auditors have the responsibility to express an opinion on the financial statements based on an audit conducted in accordance with generally accepted auditing standards. The audit committee has the responsibility to monitor and oversee these processes.

      In this context and in connection with the audited financial statements contained in Cepheid’s Annual Report on Form 10-K, the audit committee:

•  reviewed and discussed the audited financial statements with Cepheid’s management;

•  discussed with Ernst & Young LLP, Cepheid’s independent auditors, the matters required to be discussed by Statement of Auditing Standards No. 61, Communication with Audit Committees, as amended by Statement of Auditing Standards No. 90, Audit Committee Communications;

•  reviewed the written disclosures and the letter from Ernst & Young LLP required by the Independence Standards Board Standard No. 1, Independence Discussions with Audit Committees, discussed with the auditors their independence from Cepheid, and concluded that the non-audit services performed by Ernst & Young LLP are compatible with maintaining their independence;

•  based on the foregoing reviews and discussions, recommended to the board of directors that the audited financial statements be included in Cepheid’s 2004 Annual Report on Form 10-K for the fiscal year ended December 31, 2004 filed with the Securities and Exchange Commission; and

•  instructed the independent auditors that the audit committee expects to be advised if there are any subjects that require special attention.

      In addition, the audit committee selected Ernst & Young LLP as Cepheid’s independent auditors for our fiscal year ending December 31, 2005.

AUDIT COMMITTEE

Cristina H. Kepner

Dean O. Morton

Mitchell D. Mroz

Principal Accountant Fees and Services

      Ernst & Young LLP has been the independent accounting firm that audits our financial statements since our inception. In accordance with standing policy, Ernst & Young LLP periodically changes the personnel who work on the audit.

16

      In addition to performing the audit of our consolidated financial statements, Ernst & Young LLP provided various other services during 2004. The aggregate fees billed for 2004 and 2003 for each of the following categories of services are set forth below:

	2004		2003
Audit Fees	$	772,810	$	257,118
Audit-Related Fees		30,500		1,000
Tax Fees		15,000		15,000
All Other Fees		1,500		1,500

      Audit Fees. Consists of fees billed for professional services rendered for the audit of Cepheid’s annual financial statements and review of the quarterly financial statements and services, such as comfort letter, consent and comment letter, that are normally provided by Ernst & Young LLP in connection with statutory and regulatory filings or engagements. In 2004 fees related to annual audit and quarterly reviews of Cepheid’s financial statements were $341,000, fees related to SEC filings were $107,000 and fees related to compliance with requirements of the Sarbanes-Oxley Act of 2002 were $325,000. In 2003, fees related to annual audit and quarterly reviews of Cepheid’s financial statements were $237,000 another miscellaneous fees totaled $20,000.

      Audit-Related Fees. Consists of fees billed for assistance related to compliance with requirements of the Sarbanes-Oxley Act of 2002.

      Tax Fees. Consists of fees billed for professional services for tax compliance, tax advice and tax planning. These services include tax planning, assistance with the preparation of various tax returns, services rendered in connection with acquisitions and advice on other tax related matters.

      All Other Fees. Consists of fees for products and services other than the services reported above, such as the annual subscription fees of Ernst & Young Online.

      The audit committee’s policy is to pre-approve all audit and permissible non-audit services provided by the independent auditors. These services may include audit services, audit-related services, tax services and other services. Pre-approval is generally provided for up to one year and any pre-approval is detailed as to the particular service or category of services and is generally subject to a specific budget. The independent auditors and management are required to periodically report to the audit committee regarding the extent of services provided by the independent auditors in accordance with this pre-approval, and the fees for the services performed to date. The audit committee may also pre-approve particular services on a case-by-case basis.

      The audit committee has determined that the provision of non-audit services is compatible with maintaining the independence of Ernst & Young LLP.

Shareholder Proposals

      The deadline for submitting a shareholder proposal for inclusion in Cepheid’s proxy statement and form of proxy for our 2006 annual meeting of shareholders pursuant to Rule 14a-8 of the Securities and Exchange Commission is November 29, 2005. The deadline for submitting a shareholder proposal for inclusion in Cepheid’s proxy statement and form of proxy for our 2006 annual meeting of shareholders pursuant to our bylaws is December 29, 2005. Submissions must be received by Cepheid at our principal executive offices. Shareholders wishing to submit proposals or director nominations that are not to be included in our proxy statement and proxy must do so in accordance with our bylaws. Any submissions not received in the manner described above will not be considered.

Section 16(a) Beneficial Ownership Reporting Compliance

      Section 16 of the Exchange Act requires Cepheid’s directors and officers, and persons who own more than 10% of our common stock to file initial reports of ownership and reports of changes in ownership with the Securities and Exchange Commission. These persons are required by Securities and Exchange Commission regulation to furnish us with copies of all Section 16(a) forms that they file.

17

      Based solely on a review of the copies of the forms furnished to us and written representations from our executive officers and directors, we believe that all Section 16(a) filing requirements were met during our most recent fiscal year.

Shareholder Communications

      Any shareholder wishing to communicate with our board of directors regarding Cepheid may write to the board, c/o Joseph H. Smith, Secretary, Cepheid, 904 Caribbean Drive, Sunnyvale, California 94089. The Secretary of directors will forward these communications directly to the director(s). The independent directors of the board of directors review and approve the shareholder communication process periodically to ensure effective communications with shareholders.

Director Attendance at the Annual Meeting

      Cepheid’s policy is to encourage members of its board of directors to attend the annual meeting of shareholders and generally schedules a meeting of the board of directors on the date of the annual meeting to make it more convenient for them to do so.

Other Business

      The board does not presently intend to bring any other business before the meeting, and, so far as is known to the board, no matters are to be brought before the meeting except as specified in the notice of the annual meeting of shareholders. As to any business that may properly come before the meeting, however, it is intended that proxies, in the form enclosed, will be voted in respect thereof in accordance with the judgment of the persons voting the proxies.

18

PROXY

CEPHEID

PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

March 28, 2005

The undersigned shareholder of Cepheid hereby appoints John L. Bishop and John R. Sluis, and each of them with full power of substitution to each, the true and lawful attorneys, agents and proxyholders of the undersigned, and hereby authorizes them to represent and vote, as specified herein, all of the shares of common stock of Cepheid held of record by the undersigned on March 4, 2005, at the annual meeting of shareholders of Cepheid to be held on April 28, 2005 (the “Annual Meeting”) at 1:00 p.m. at Cepheid’s principal executive offices, 904 Caribbean Drive Sunnyvale, California 94089 and any adjournments or postponements thereof.

CONTINUED AND TO BE SIGNED ON THE REVERSE SIDE

þ Please mark votes as in this example

THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED IN THE MANNER DIRECTED. IN THE ABSENCE OF DIRECTION, THE SHARES WILL BE VOTED FOR THE PROPOSALS.

THE UNDERSIGNED ACKNOWLEDGES RECEIPT OF THE NOTICE OF ANNUAL MEETING OF SHAREHOLDERS RELATING TO THE ANNUAL MEETING.

1.   To elect three Class III directors of Cepheid to serve on the board of directors for a three-year term. The board of directors intends to present the following nominees for election as directors:

Vote FOR all the nominees (except as directed to the contrary)
                                                                                     o

Vote WITHHELD from all nominees                      o

Robert J. Easton
Hollings C. Renton
Mitchell D. Mroz

INSTRUCTIONS: To withhold vote for any individual nominee, write the nominee’s name in the space provided below:

2.   To ratify the appointment of Ernst & Young LLP as independent auditors of Cepheid for the fiscal year ending December 31, 2005.

For
o Against
o Abstain
o

MARK HERE FOR ADDRESS CHANGE AND NOTE AT LEFT o

Please sign exactly as name appears hereon. Joint owners should each sign. Trustees and others acting in a representative capacity should indicate the capacity in which they sign and give their full title. If a corporation, please have an authorized officer sign and indicate the full corporate name. If a partnership, please sign in partnership name by an authorized person.

MARK HERE IF YOU PLAN ON ATTENDING THE SHAREHOLDER MEETING o

Please mark, sign and date this proxy and return it promptly whether you plan to attend the meeting or not. If you do attend, you may vote in person if you desire.

Signature: Date: Signature: Date:

Print Name: Print Name: